Falchook, Gerald S <br/><br/>
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.  [electronic resource] 

 -  Investigational new drugs  Feb 2015 
 - 215-24 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-014-0176-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bevacizumab<br/>Class I Phosphatidylinositol 3-Kinases<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Mutation<br/>Neoplasms--drug therapy<br/>Niacinamide--administration & dosage<br/>PTEN Phosphohydrolase--genetics<br/>Phenylurea Compounds--administration & dosage<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Polymorphism, Single Nucleotide<br/>Proto-Oncogene Proteins--genetics<br/>Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors<br/>Sorafenib<br/>Tumor Suppressor Protein p53--genetics<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors